XERIS BIOPHARMA HOLDINGS, INC.
Assets & Liabilities
| Period | Total Liabilities | Total Assets | Cash on Hand |
|---|---|---|---|
| Mar 2022 | $241.2M | $337.6M | $103.8M |
| Jun 2022 | $244.7M | $318.6M | $95.3M |
| Sep 2022 | $248.0M | $303.0M | $84.1M |
| Dec 2022 | $299.3M | $344.5M | $122.0M |
| Mar 2023 | $291.3M | $321.4M | $51.0M |
| Jun 2023 | $315.1M | $328.8M | $46.2M |
| Sep 2023 | $323.9M | $327.8M | $46.1M |
| Dec 2023 | $329.4M | $322.6M | $67.4M |
| Mar 2024 | $345.8M | $336.6M | $62.7M |
| Jun 2024 | $351.0M | $331.7M | $57.6M |
| Sep 2024 | $349.4M | $321.1M | $59.2M |
| Dec 2024 | $352.7M | $323.1M | $71.6M |
| Mar 2025 | $350.6M | $315.5M | $58.4M |
| Jun 2025 | $354.0M | $334.7M | $59.3M |
| Sep 2025 | $371.1M | $370.2M | $91.6M |
| Dec 2025 | $369.8M | $383.5M | $111.0M |
| Mar 2026 | $379.0M | $392.0M | $111.8M |
| Jun 2026 | $421.6M | $411.9M | $121.7M |